Allergy Therapeutics plc has disclosed a Form 8.5 (EPT/RI) from Panmure Gordon (UK) Limited, an exempt principal trader with recognized intermediary status. The form provides key information regarding dealings in Allergy Therapeutics' securities. The date of dealing was October 27, 2023. The form includes details of purchases and sales of the company's 0.1p ordinary shares, with 5,000 shares purchased at a highest price of 0.01316 per unit and 713,699 shares sold at a highest price of 0.0144 per unit. The lowest price per unit paid/received for both purchases and sales was 0.01316 and 0.01408, respectively.
The form does not disclose any cash-settled derivative transactions or stock-settled derivative transactions, including options. It also states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities that may be an inducement to deal or refrain from dealing. Additionally, there are no agreements, arrangements, or understandings relating to options or derivatives.
The contact person for this disclosure is Freddie Wooding, and the date of disclosure is October 30, 2023. The form emphasizes that public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service, and the Panel's Market Surveillance Unit is available for consultation regarding the Code's dealing disclosure requirements.